The divestiture is expected to sharpen Clarivate’s focus on its Academia & Government and Intellectual Property businesses, improve its financial profile, and support debt reduction.Clarivate Sells Life Sciences & Healthcare UnitUnder the agreement, Clarivate will receive $500 million in cash at closing, $25 million upon completion of a transition services agreement, and a $75 million seller note.The company plans to use the cash proceeds to reduce debt. Clarivate said the sale will improve its revenue mix, lower capital intensity, and expand adjusted EBITDA margin.Outlook Reaffirmed, Impairment ExpectedClarivate reaffirmed its full-year 2026 financial outlook, including LS&H results.The company expects to classify LS&H as discontinued operations starting in the third quarter and update its full-year outlook after the transaction closes.Clarivate also expects to record a $225 million to $250 million non-cash goodwill impairment tied to LS&H. The company said the impairment will not affect the financial metrics in its full-year outlook.Sharper Focus On Core SegmentsAfter the deal closes, Clarivate will operate as a subscription-first provider of intelligence solutions, workflow software, and tech-enabled services. The company’s remaining business will focus on Academia & Government and Intellectual Property.CFO Jonathan Collins said: “This strategic divestiture strengthens Clarivate’s financial profile and accelerates our debt reduction plan. Moreover, monetizing the LS&H segment will enhance the quality of our revenue mix, lower capital intensity, and improve margins. The result is a streamlined Company with increased financial flexibility to support long-term growth and disciplined capital allocation.”Analyst Consensus And Recent ActionsThe stock carries a Hold rating with an average price target of $2.95. Recent analyst moves include: